Almirall, S.A. (LON:0O9B)

Market Cap	2.17B +19.9%
Revenue (ttm)	978.68M +9.0%
Net Income	34.80M +63.7%
EPS	n/a
Shares Out	n/a
PE Ratio	62.37
Forward PE	28.93
Dividend	0.13 (1.08%)
Ex-Dividend Date	May 15, 2025

Volume	27
Average Volume	48,746
Open	12.10
Previous Close	11.78
Day's Range	11.60 - 11.94
52-Week Range	9.85 - 13.98
Beta	0.20
RSI	31.77
Earnings Date	May 11, 2026

About Almirall

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal sys...

• Industry: Pharmaceutical Preparations
• Founded: 1943
• Employees: 2,108
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0O9B

Financial Performance

In 2025, Almirall's revenue was 1.11 billion, an increase of 12.51% compared to the previous year's 990.63 million. Earnings were 46.15 million, an increase of 354.85%.

Financial numbers in EUR